Cargando…

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib

Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor approved for the treatment of RR-DTC. This study aims to assess Eastern Cooperative Oncology Group performance status (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Matthew H., Takahashi, Shunji, Capdevila, Jaume, Tahara, Makoto, Leboulleux, Sophie, Kiyota, Naomi, Dutcus, Corina E., Xie, Ran, Robinson, Bruce, Sherman, Steven, Habra, Mouhammed Amir, Elisei, Rossella, Wirth, Lori J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Thyroid Cancer and Nodules
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377516/ https://www.ncbi.nlm.nih.gov/pubmed/33637020 http://dx.doi.org/10.1089/thy.2020.0779

Ejemplares similares

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
por: Capdevila, Jaume, et al.
Publicado: (2022)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event
por: Monti, Salvatore, et al.
Publicado: (2022)

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
por: Dierks, Christine, et al.
Publicado: (2021)

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
por: Capdevila, Jaume, et al.
Publicado: (2023)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

Hurthle Cells Adenoma With Distant Metastases Refractory to Radioiodine
por: Rosario, Pedro Weslley, et al.
Publicado: (2021)

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
por: Robinson, Bruce, et al.
Publicado: (2016)

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Brose, Marcia S, et al.
Publicado: (2021)

MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)
por: Wirth, Lori J, et al.
Publicado: (2020)

Effects of Pregnancy on Papillary Microcarcinomas of the Thyroid Re-Evaluated in the Entire Patient Series at Kuma Hospital
por: Ito, Yasuhiro, et al.
Publicado: (2016)

Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery
por: Oda, Hitomi, et al.
Publicado: (2016)

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology
por: Nikiforov, Yuri E., et al.
Publicado: (2015)

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation
por: Nikita, Maria Eleni, et al.
Publicado: (2016)

Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study
por: Dobnig, Harald, et al.
Publicado: (2018)

Trends in the Implementation of Active Surveillance for Low-Risk Papillary Thyroid Microcarcinomas at Kuma Hospital: Gradual Increase and Heterogeneity in the Acceptance of This New Management Option
por: Ito, Yasuhiro, et al.
Publicado: (2018)

Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study
por: Mathiesen, Jes Sloth, et al.
Publicado: (2019)

Molecular Classification of Thyroid Nodules with Indeterminate Cytology: Development and Validation of a Highly Sensitive and Specific New miRNA-Based Classifier Test Using Fine-Needle Aspiration Smear Slides
por: dos Santos, Marcos Tadeu, et al.
Publicado: (2018)

Impact of Extranodal Extension on Risk Stratification in Papillary Thyroid Carcinoma
por: Kim, Hye In, et al.
Publicado: (2019)

Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy
por: Schürch, Christian M., et al.
Publicado: (2019)

Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994–2014: A Nationwide Study
por: Mathiesen, Jes Sloth, et al.
Publicado: (2017)

A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study
por: González, Hernán E., et al.
Publicado: (2017)

A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology
por: Kloos, Richard T., et al.
Publicado: (2016)

A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer
por: Sawka, Anna M., et al.
Publicado: (2020)

Patients' View on the Management of Papillary Thyroid Microcarcinoma: Active Surveillance or Surgery
por: Yoshida, Yusaku, et al.
Publicado: (2020)

A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials
por: Zafereo, Mark, et al.
Publicado: (2020)

Routine Chest Computed Tomography at Presentation Does Not Identify Distant Metastasis in cT1aN0 Papillary Thyroid Carcinoma
por: Kawano, Shiori, et al.
Publicado: (2020)

Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules
por: Goldner, Whitney S., et al.
Publicado: (2019)

Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer
por: Masoodi, Tariq, et al.
Publicado: (2020)

Kinetic Analysis of Growth Activity in Enlarging Papillary Thyroid Microcarcinomas
por: Ito, Yasuhiro, et al.
Publicado: (2019)

The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients
por: Craig, Steven J., et al.
Publicado: (2020)

Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan
por: Sugitani, Iwao, et al.
Publicado: (2019)

Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
por: Sasaki, Takahiro, et al.
Publicado: (2021)

Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples
por: Kaya, Cihan, et al.
Publicado: (2021)

A Positive Feedback Loop Between DICER1 and Differentiation Transcription Factors Is Important for Thyroid Tumorigenesis
por: Ramírez-Moya, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gkem82ab4ttbn2ef8utcu8s1gg